Topical Gene Therapy Vyjuvek & Cancer Drug Lynozyfic Among Four New Products Set For EU Market

The European Medicines Agency has recommended in favor of approving four new products, and has also reaffirmed its positive opinion for the Alzheimer’s disease drug, Leqembi.

Four products were backed for approval by the EMA this week (Shutterstock)
Key Takeaways
  • Krystal Biotech’s Vyjuvek, Regeneron’s Lynozyfic, Takeda’s Deqsiga and Accord Healthcare’s Accord Trabectedin have been backed for pan-EU approval by the European Medicines Agency

Vyjuvek (beremagene geperpavec), Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), could be...

More from EU CHMP

More from Pathways & Standards